Total Clarity Wealth Management Inc. Has $174,000 Stake in uniQure N.V. $QURE

Total Clarity Wealth Management Inc. trimmed its position in shares of uniQure N.V. (NASDAQ:QURE) by 18.9% during the second quarter, HoldingsChannel reports. The institutional investor owned 12,450 shares of the biotechnology company’s stock after selling 2,900 shares during the period. Total Clarity Wealth Management Inc.’s holdings in uniQure were worth $174,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. KLP Kapitalforvaltning AS bought a new position in shares of uniQure in the 2nd quarter valued at $117,000. Mraz Amerine & Associates Inc. bought a new position in shares of uniQure in the 1st quarter valued at $106,000. OMERS ADMINISTRATION Corp bought a new position in shares of uniQure in the 1st quarter valued at $152,000. XTX Topco Ltd increased its stake in shares of uniQure by 127.3% in the 1st quarter. XTX Topco Ltd now owns 36,999 shares of the biotechnology company’s stock valued at $392,000 after purchasing an additional 20,720 shares during the last quarter. Finally, Rafferty Asset Management LLC bought a new position in shares of uniQure in the 1st quarter valued at $875,000. Institutional investors own 78.83% of the company’s stock.

Wall Street Analysts Forecast Growth

QURE has been the topic of several recent analyst reports. Leerink Partners lifted their price target on uniQure from $48.00 to $68.00 and gave the company an “outperform” rating in a research note on Wednesday, September 24th. Wells Fargo & Company lifted their price target on uniQure from $65.00 to $80.00 and gave the company an “overweight” rating in a research note on Thursday, October 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of uniQure in a research report on Wednesday, October 8th. Chardan Capital boosted their price objective on uniQure from $35.00 to $76.00 and gave the stock a “buy” rating in a research report on Thursday, September 25th. Finally, Stifel Nicolaus boosted their price objective on uniQure from $30.00 to $65.00 and gave the stock a “buy” rating in a research report on Wednesday, September 24th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $71.75.

uniQure Stock Down 4.9%

Shares of QURE opened at $58.96 on Wednesday. The company has a market capitalization of $3.24 billion, a PE ratio of -15.04 and a beta of 0.56. uniQure N.V. has a 12 month low of $5.35 and a 12 month high of $65.12. The stock’s 50-day moving average price is $27.96 and its two-hundred day moving average price is $18.61. The company has a current ratio of 9.98, a quick ratio of 9.98 and a debt-to-equity ratio of 1.53.

uniQure (NASDAQ:QURE) last announced its earnings results on Tuesday, July 29th. The biotechnology company reported ($0.69) EPS for the quarter, topping the consensus estimate of ($0.89) by $0.20. The firm had revenue of $5.26 million for the quarter, compared to the consensus estimate of $5.00 million. uniQure had a negative return on equity of 1,010.74% and a negative net margin of 1,387.98%. On average, analysts anticipate that uniQure N.V. will post -3.75 EPS for the current year.

Insider Activity

In other uniQure news, CEO Matthew C. Kapusta sold 226,316 shares of uniQure stock in a transaction dated Wednesday, September 24th. The stock was sold at an average price of $41.46, for a total transaction of $9,383,061.36. Following the transaction, the chief executive officer directly owned 651,454 shares of the company’s stock, valued at approximately $27,009,282.84. The trade was a 25.78% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Christian Klemt sold 15,000 shares of uniQure stock in a transaction dated Friday, September 26th. The stock was sold at an average price of $55.00, for a total value of $825,000.00. Following the transaction, the chief financial officer directly owned 217,730 shares in the company, valued at $11,975,150. The trade was a 6.45% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 244,316 shares of company stock worth $10,328,181 over the last ninety days. Company insiders own 4.79% of the company’s stock.

uniQure Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.